Sanai Health Industry : VOLUNTARY ANNOUNCEMENT SUSPENSION OF FACTORY OPERATION; PHARMACEUTICAL PRODUCTS SALES BUSINESS; AND FINANCE LEASE BUSINESS

Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sanai Health Industry Group Company Limited

三 愛 健 康 產 業 集 團 有 限 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1889)

VOLUNTARY ANNOUNCEMENT

SUSPENSION OF FACTORY OPERATION;

PHARMACEUTICAL PRODUCTS SALES BUSINESS;

AND

FINANCE LEASE BUSINESS

This is a voluntary announcement made by Sanai Health Industry Group Company Limited (the ''Company'', together with its subsidiaries, the ''Group'').

Since the outbreak of the new coronavirus pneumonia epidemic (the ''Epidemic'') in the People's Republic of China (the ''PRC''), a number of provinces and municipalities in the PRC have taken emergency public health measures and various actions to prevent the spread of the Epidemic. The government of the PRC issued notices to extend the period of Chinese New Year holiday in the PRC.

The Group actively devotes its efforts to facilitate the prevention and control of the Epidemic and to ensure the health and safety of the Group's employees in the PRC. The board of directors of the Company (the ''Board'') hereby announces that the Company will comply with the relevant requirements for the prevention and control of the Epidemic issued by the government of the PRC by suspension of factory operation of Fujian Yongchun Pharmaceutical Co., Ltd.* (福建永春製藥有限公司) (''Fujian Yongchun''), pharmaceutical products sales business of Fujian Zhixin Pharmaceutical Co., Ltd.* (福建至信醫藥有限公司) (''Fujian Zhixin'') and finance lease business of the Group in Shenzhen, the PRC temporarily. The factory operation of Fujian Yongchun, pharmaceutical products sales business of Fujian Zhixin and finance lease business of the Group in Shenzhen, the PRC are expected to resume on 16 February 2020. If the suspension needs to be extended further in response to the development of the Epidemic and/or pronouncement of further policies or measures by the government of the PRC, the Company will make further announcement(s) as and when necessary. The Group has informed the customers that there may be delay in the original shipments schedule due to the suspension of factory operation of Fujian Yongchun and pharmaceutical products sales business of Fujian Zhixin. Although such delay is caused by event which is beyond the control of the Group, the Group will use its best endeavours to meet the original shipments schedule as much as possible.

- 1 -

Trading suspension

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on Friday, 24 January 2020 and will remain suspended until further notice.

Shareholders and potential investors of the Company are advised not to place undue reliance on the aforesaid information but to exercise caution when dealing in the shares of the Company.

By order of the Board

Sanai Health Industry Group Company Limited

Chen Chengqing

Chairman

Hong Kong, 10 February 2020

As at the date of this announcement, the Board comprises five executive directors, namely, Mr. Chen Chengqing (Chairman), Mr. Gao Borui, Mr. Yuan Chaoyang, Professor Zhang Rongqing and Mr. She Hao, one non-executive director, namely, Mr. Xiu Yuan and three independent non-executive directors, namely, Mr. Tu Fangkui, Mr. Wang Zihao, and Mr. Long Jun.

• For identification purpose only

- 2 -